NASD · Healthcare · Diagnostics & Research · USA
Medpace Holdings Inc is a large cap company (market value between $10 billion and $200 billion) in the Diagnostics & Research industry.
Medpace Holdings is a clinical contract research organization offering outsourced development support to companies in biotechnology, pharmaceuticals and medical devices. The organization delivers Phase I-IV trial management across therapeutic areas including Oncology, Metabolic, Cardiology and Central Nervous System conditions. Its services span medical direction, site coordination, patient enrollment, regulatory guidance, laboratory analysis and quality oversight.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Medpace Holdings Inc stock.
Overvalued: intrinsic value $487.08 per share, market price $619.66, margin of safety -27.2% (as of 2026-10-19).
Discounting its cash flows at 10.5% (average of 3 methods) values the shares at $487.08; the price of $619.66 is 27% above that value, and 73% of that value comes from beyond year five.
Leak Score: 82/100 on 11 of 12 signals (Strong Leak).
17 more funds hold it; the full list is part of the paid plan.
All 44 Diagnostics & Research stocks
MEDP is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 10.5% (average of 3 methods) values the shares at $487.08; the price of $619.66 is 27% above that value, and 73% of that value comes from beyond year five.
$487.08 per share (as of the 2026-10-19 close), against a market price of $619.66. That is a margin of safety of -27.2%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
82 out of 100, which we rate "Strong Leak", on 11 of 12 value investing signals.